Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-26T14:27:14.577Z Has data issue: false hasContentIssue false

Excessive activation of the loop between the NR2B subunit of the N-methyl-d-aspartate receptor and glycogen synthase kinase-3β in the hippocampi of patients with major depressive disorder

Published online by Cambridge University Press:  24 June 2014

Dong Hoon Oh
Affiliation:
Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul, Korea
Seon-Cheol Park
Affiliation:
Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul, Korea
Yong Chon Park
Affiliation:
Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul, Korea
Seok Hyeon Kim*
Affiliation:
Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul, Korea
*
Professor Seok Hyeon Kim, Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Haengdang 1-dong, Seongdong-gu, Seoul 133-792, Korea. Tel: +82 2 2290 8426; Fax: +82 2 2298 2055; E-mail: [email protected]

Extract

Objective: We showed previously that glycogen synthase kinase-3β (GSK-3β) levels are significantly elevated in the hippocampi of patients with major depressive disorder (MDD). However, the exact cause of this elevation and its function are unknown. Recent animal studies have suggested a mechanism involving the N-methyl-d-aspartate (NMDA) NR2B–GSK-3β loop.

Methods: To investigate the existence of an NR2B–GSK-3β loop in the hippocampi of patients with MDD, we examined the expression of NR2B. We also attempted to identify markers that correlate with NR2B levels in the hippocampus, using the Stanley Neuropathology Consortium Integrative Database (SNCID). The SNCID is a web-based tool used to integrate Stanley Medical Research Institute (SMRI) data sets.

Results: We found that hippocampal levels of NR2B and DLGAP1 mRNA were higher in the MDD group (n = 8) than in unaffected controls (n = 12) (p < 0.05). NR2B expression levels were correlated with the expression levels of NR2A, NR1, DLGAP1, GSK-3β and nitric oxide synthase 1, as well as with the number of calretinin-immunoreactive neurons in the hippocampus in all subjects in the SNC (n = 42, p < 0.001).

Conclusion: The results of our study show the possible involvement of excessive activation of the NR2B–GSK-3β loop in the overexpression of GSK-3β in the hippocampi of patients with MDD.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Silva, R, Mesquita, AR, Bessa, J et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008;152:656669.CrossRefGoogle ScholarPubMed
2.Oh, DH, Park, YC, Kim, SH.Increased glycogen synthase kinase-3beta mRNA level in the hippocampus of patients with major depression: a study using the stanley neuropathology consortium integrative database. Psychiatry Investig 2010;7:202207.CrossRefGoogle ScholarPubMed
3.Facci, L, Stevens, DA, Skaper, SD.Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 2003;14:14671470.CrossRefGoogle ScholarPubMed
4.Szatmari, E, Habas, A, Yang, P, Zheng, JJ, Hagg, T, Hetman, M.A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem 2005;280:3752637535.CrossRefGoogle ScholarPubMed
5.Chen, P, Gu, Z, Liu, W, Yan, Z.Glycogen synthase kinase 3 regulates N-methyl-d-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol 2007;72:4051.CrossRefGoogle ScholarPubMed
6.De Sarno, P, Bijur, GN, Zmijewska, AA, Li, X, Jope, RS.In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol Aging 2006;27:413422.CrossRefGoogle ScholarPubMed
7.Torrey, EF, Webster, M, Knable, M, Johnston, N, Yolken, RH.The stanley foundation brain collection and neuropathology consortium. Schizophr Res 2000;44: 151155.CrossRefGoogle ScholarPubMed
8.Kim, S, Webster, MJ.The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 2010;35:473482.CrossRefGoogle ScholarPubMed
9.Kim, S, Webster, MJ.Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010;15:326336.CrossRefGoogle ScholarPubMed
10.Beneyto, M, Kristiansen, LV, Oni-Orisan, A, McCullumsmith, RE, Meador-Woodruff, JH.Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007;32:18881902.CrossRefGoogle ScholarPubMed
11.Karolewicz, B, Stockmeier, CA, Ordway, GA.Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 2005;30:15571567.CrossRefGoogle ScholarPubMed
12.Toro, C, Deakin, JF.NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 2005;80:323330.CrossRefGoogle ScholarPubMed
13.Beneyto, M, Meador-Woodruff, JH.Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008;33: 21752186.CrossRefGoogle ScholarPubMed
14.Feyissa, AM, Chandran, A, Stockmeier, CA, Karolewicz, B.Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:7075.CrossRefGoogle ScholarPubMed
15.Karolewicz, B, Szebeni, K, Gilmore, T, Maciag, D, Stockmeier, CA, Ordway, GA.Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2009;12:143153.CrossRefGoogle ScholarPubMed
16.Sheng, M.The postsynaptic NMDA-receptor–PSD-95 signaling complex in excitatory synapses of the brain. J Cell Sci 2001;114:1251.CrossRefGoogle ScholarPubMed
17.Cui, H, Hayashi, A, Sun, HS et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 2007;27:99019915.CrossRefGoogle ScholarPubMed
18.Khovryakov, AV, Podrezova, EP, Kruglyakov, PP et al. Involvement of the NO synthase system in stress-mediated brain reactions. Neurosci Behav Physiol 2010;40:333337.CrossRefGoogle ScholarPubMed
19.Zhou, QG, Hu, Y, Hua, Y et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007;103:18431854.CrossRefGoogle ScholarPubMed
20.Oliveira, RM, Guimaraes, FS, Deakin, JF.Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41:333341.CrossRefGoogle ScholarPubMed
21.Camp, AJ, Wijesinghe, R.Calretinin: modulator of neuronal excitability. Int J Biochem Cell Biol 2009;41:21182121.CrossRefGoogle ScholarPubMed
22.Fonseca, M, Soriano, E.Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res 1995;691:8391.CrossRefGoogle ScholarPubMed
23.Brandt, MD, Jessberger, S, Steiner, B et al. Transient calretinin expression defines early postmitotic step of neuronal differentiation in adult hippocampal neurogenesis of mice. Mol Cell Neurosci 2003;24:603613.CrossRefGoogle ScholarPubMed
24.Nitsch, R, Ohm, TG.Calretinin immunoreactive structures in the human hippocampal formation. J Comp Neurol 1995;360:475487.CrossRefGoogle ScholarPubMed
25.Zhang, ZJ, Reynolds, GP.A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55:110.CrossRefGoogle ScholarPubMed